Clinical trial · Observational
Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses.
Diagnostic Role of Circulating microRNAs in Small Testicular Masses Suitable for Testis Sparing Surgery and Post-chemotherapy Residual Masses Suitable for Retroperitoneal Lymph Node Dissection.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the diagnostic performance of circulating microRNAs in detecting the presence of germ cell cancer in patients with small testicular mass or retroperitoneal post-chemotherapy residual mass and suitable for testis sparing surgery and retroperitoneal lymph node dissection, respectively.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Testicular Cancer | Malignant Testicular Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Circulating microRNAs. | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- A
- description
- Small testicular mass suitable for testis sparing surgery.
- interventionNames
- Diagnostic Test: Circulating microRNAs.
- label
- B
- description
- Retroperitoneal post-chemotherapy residual mass suitable for retroperitoneal lymph node dissection.
- interventionNames
- Diagnostic Test: Circulating microRNAs.
Primary outcomes (2)
- measure
- MicroRNA's germ cell cancer detection (Cohort A)
- timeFrame
- Baseline.
- description
- Preoperative circulating microRNA's diagnostic accuracy in detecting germ cell cancer in patients with small testicular mass and submitted to testis sparing surgery, using post-operative surgical specimen as reference.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
COHORT A: Inclusion Criteria: * Age \>= 18 years * Single testicular lesion, with \< 2 cm diameter and \< 30 % testicular volume involvement; * Negative Serum Tumour Markers; * Suitable for testis sparing surgery; * Informed consent. Exclusion Criteria: * None COHORT B: Inclusion Criteria: * Age \>= 18 years * Single/multiple post-chemotherapy retroperitoneal lymph node lesion, with \> 1 cm (non seminomatous) / \> 3 cm (seminomatous) diameter in patients with previous testicular germ cell primary tumour; * Negative Serum Tumour Markers; * Suitable for retroperitoneal lymph node dissection; * Informed consent. Exclusion Criteria: * None
References
Publications (0)
Data not yet available